Efficacy of nafimidone in the treatment of intractable partial seizures: Report of a two-center pilot study

D. M. Treiman, A. J. Wilensky, E. Ben-Menachem, L. Ojemann, M. Yerby, K. O. Barber, K. B. McCormick, James Cereghino, B. G. White, K. Swisher

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Nafimidone is a potential new antiepileptic drug with a therapeutic profile in experimental animal seizure models similar to that of phenytoin (PHT). We report here the first clinical trial of nafimidone in epileptic patients. Twelve adult male patients with a mean of four or more medically intractable seizures per month were enrolled in a 14-week pilot study. Patients were stabilized on therapeutic levels of PHT and carbamazepine (CBZ) (nine patients) or on PHT alone (three patients) before entering a 4-week baseline period. Nafimidone, to a maximum dose of 600 mg/day, was added during 2 weeks in hospital. Patients were then evaluated weekly for 8 weeks. Eight patients experienced 33-98% improvement in seizure control. Three others did not show significant change in seizure frequency but experienced sufficient subjective improvement that they continued into long-term follow-up. One patient, who had a 63% improvement in mean weekly seizures during the pilot study, declined to continue. Thus, 10 patients entered long-term follow-up. Six of the 10 sustained 53 to >99% improvement in seizure control compared with baseline over the course of 46-53 weeks of follow-up. Nafimidone had a marked inhibitory effect on the clearance of CBZ and PHT, resulting in higher plasma levels in nine patients. The possible role of the elevated CBZ levels in the apparent efficacy of nafimidone is discussed.

Original languageEnglish (US)
Pages (from-to)607-611
Number of pages5
JournalEpilepsia
Volume26
Issue number6
StatePublished - 1985
Externally publishedYes

Fingerprint

Seizures
Phenytoin
Carbamazepine
Therapeutics
nafimidone
Anticonvulsants
Animal Models
Clinical Trials

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Treiman, D. M., Wilensky, A. J., Ben-Menachem, E., Ojemann, L., Yerby, M., Barber, K. O., ... Swisher, K. (1985). Efficacy of nafimidone in the treatment of intractable partial seizures: Report of a two-center pilot study. Epilepsia, 26(6), 607-611.

Efficacy of nafimidone in the treatment of intractable partial seizures : Report of a two-center pilot study. / Treiman, D. M.; Wilensky, A. J.; Ben-Menachem, E.; Ojemann, L.; Yerby, M.; Barber, K. O.; McCormick, K. B.; Cereghino, James; White, B. G.; Swisher, K.

In: Epilepsia, Vol. 26, No. 6, 1985, p. 607-611.

Research output: Contribution to journalArticle

Treiman, DM, Wilensky, AJ, Ben-Menachem, E, Ojemann, L, Yerby, M, Barber, KO, McCormick, KB, Cereghino, J, White, BG & Swisher, K 1985, 'Efficacy of nafimidone in the treatment of intractable partial seizures: Report of a two-center pilot study', Epilepsia, vol. 26, no. 6, pp. 607-611.
Treiman DM, Wilensky AJ, Ben-Menachem E, Ojemann L, Yerby M, Barber KO et al. Efficacy of nafimidone in the treatment of intractable partial seizures: Report of a two-center pilot study. Epilepsia. 1985;26(6):607-611.
Treiman, D. M. ; Wilensky, A. J. ; Ben-Menachem, E. ; Ojemann, L. ; Yerby, M. ; Barber, K. O. ; McCormick, K. B. ; Cereghino, James ; White, B. G. ; Swisher, K. / Efficacy of nafimidone in the treatment of intractable partial seizures : Report of a two-center pilot study. In: Epilepsia. 1985 ; Vol. 26, No. 6. pp. 607-611.
@article{7167a6b841d544a5ab0d3ee99ceef629,
title = "Efficacy of nafimidone in the treatment of intractable partial seizures: Report of a two-center pilot study",
abstract = "Nafimidone is a potential new antiepileptic drug with a therapeutic profile in experimental animal seizure models similar to that of phenytoin (PHT). We report here the first clinical trial of nafimidone in epileptic patients. Twelve adult male patients with a mean of four or more medically intractable seizures per month were enrolled in a 14-week pilot study. Patients were stabilized on therapeutic levels of PHT and carbamazepine (CBZ) (nine patients) or on PHT alone (three patients) before entering a 4-week baseline period. Nafimidone, to a maximum dose of 600 mg/day, was added during 2 weeks in hospital. Patients were then evaluated weekly for 8 weeks. Eight patients experienced 33-98{\%} improvement in seizure control. Three others did not show significant change in seizure frequency but experienced sufficient subjective improvement that they continued into long-term follow-up. One patient, who had a 63{\%} improvement in mean weekly seizures during the pilot study, declined to continue. Thus, 10 patients entered long-term follow-up. Six of the 10 sustained 53 to >99{\%} improvement in seizure control compared with baseline over the course of 46-53 weeks of follow-up. Nafimidone had a marked inhibitory effect on the clearance of CBZ and PHT, resulting in higher plasma levels in nine patients. The possible role of the elevated CBZ levels in the apparent efficacy of nafimidone is discussed.",
author = "Treiman, {D. M.} and Wilensky, {A. J.} and E. Ben-Menachem and L. Ojemann and M. Yerby and Barber, {K. O.} and McCormick, {K. B.} and James Cereghino and White, {B. G.} and K. Swisher",
year = "1985",
language = "English (US)",
volume = "26",
pages = "607--611",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Efficacy of nafimidone in the treatment of intractable partial seizures

T2 - Report of a two-center pilot study

AU - Treiman, D. M.

AU - Wilensky, A. J.

AU - Ben-Menachem, E.

AU - Ojemann, L.

AU - Yerby, M.

AU - Barber, K. O.

AU - McCormick, K. B.

AU - Cereghino, James

AU - White, B. G.

AU - Swisher, K.

PY - 1985

Y1 - 1985

N2 - Nafimidone is a potential new antiepileptic drug with a therapeutic profile in experimental animal seizure models similar to that of phenytoin (PHT). We report here the first clinical trial of nafimidone in epileptic patients. Twelve adult male patients with a mean of four or more medically intractable seizures per month were enrolled in a 14-week pilot study. Patients were stabilized on therapeutic levels of PHT and carbamazepine (CBZ) (nine patients) or on PHT alone (three patients) before entering a 4-week baseline period. Nafimidone, to a maximum dose of 600 mg/day, was added during 2 weeks in hospital. Patients were then evaluated weekly for 8 weeks. Eight patients experienced 33-98% improvement in seizure control. Three others did not show significant change in seizure frequency but experienced sufficient subjective improvement that they continued into long-term follow-up. One patient, who had a 63% improvement in mean weekly seizures during the pilot study, declined to continue. Thus, 10 patients entered long-term follow-up. Six of the 10 sustained 53 to >99% improvement in seizure control compared with baseline over the course of 46-53 weeks of follow-up. Nafimidone had a marked inhibitory effect on the clearance of CBZ and PHT, resulting in higher plasma levels in nine patients. The possible role of the elevated CBZ levels in the apparent efficacy of nafimidone is discussed.

AB - Nafimidone is a potential new antiepileptic drug with a therapeutic profile in experimental animal seizure models similar to that of phenytoin (PHT). We report here the first clinical trial of nafimidone in epileptic patients. Twelve adult male patients with a mean of four or more medically intractable seizures per month were enrolled in a 14-week pilot study. Patients were stabilized on therapeutic levels of PHT and carbamazepine (CBZ) (nine patients) or on PHT alone (three patients) before entering a 4-week baseline period. Nafimidone, to a maximum dose of 600 mg/day, was added during 2 weeks in hospital. Patients were then evaluated weekly for 8 weeks. Eight patients experienced 33-98% improvement in seizure control. Three others did not show significant change in seizure frequency but experienced sufficient subjective improvement that they continued into long-term follow-up. One patient, who had a 63% improvement in mean weekly seizures during the pilot study, declined to continue. Thus, 10 patients entered long-term follow-up. Six of the 10 sustained 53 to >99% improvement in seizure control compared with baseline over the course of 46-53 weeks of follow-up. Nafimidone had a marked inhibitory effect on the clearance of CBZ and PHT, resulting in higher plasma levels in nine patients. The possible role of the elevated CBZ levels in the apparent efficacy of nafimidone is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0022366115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022366115&partnerID=8YFLogxK

M3 - Article

C2 - 3935425

AN - SCOPUS:0022366115

VL - 26

SP - 607

EP - 611

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 6

ER -